The decision fortifies the company’s long-term commercial potential as it prepares to initiate Phase 3 trial activities in Multiple System Atrophy by year-end 2026.
Alterity Therapeutics Intellectual Property Portfolio Expansion
The USPTO granted the patent entitled “Crystalline Form, and Process for its Production,” which covers the composition of matter of a crystalline form of ATH434 mesylate alongside methods for treating neurological conditions using it.
Protecting this novel solid-state crystalline form and treatment methods provides another vital layer of commercial protection for treating Multiple System Atrophy and additional neurodegenerative disorders.
This specific form of the mesylate salt was used during the company’s Phase 2 clinical trials in Multiple System Atrophy and will be used in the planned Phase 3 study.
ATH434 itself is designed as an oral agent to target the underlying pathology of neurodegenerative conditions.
Extended Commercial Runway And FDA Listing
With an estimated expiration date extending to at least 2045, the patent works together with existing intellectual property and regulatory designations to provide multi-layered market protection.
Upon regulatory approval for commercialization, the FDA is expected to list ATH434 in its Approved Drug Products with Therapeutic Equivalence Evaluations publication, known as the Orange Book.
The newly granted patent enables future clinical development opportunities for ATH434 in Parkinson’s disease and other neurodegenerative diseases where iron dysregulation and protein aggregation are implicated in disease pathology.
ATHE Stock Price Activity: Alterity Therapeutics shares were up 0.21% at $4.70 during premarket trading on Wednesday, according to Benzinga Pro data.
Kateryna Kon via Shutterstock
Leave a comment